ALX Oncology

Update in progress

ALXO (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on developing cancer therapies in the United States. Its lead candidate, Evorpacept, is a CD47-blocking biologic studied as a combination therapy in gastric/GEJ cancer (ASPEN-06, Phase 2). The company collaborates with Jazz Pharmaceuticals on zanidatamab (Phase 1b/2 for breast cancer and other solid tumors), with Sanofi on isatuximab/dexamethasone (Phase 1/2 multiple myeloma), with MD Anderson on rituximab plus lenalidomide for NHL, and with Stanford for licenses. Incorporated 2015; HQ in South San Francisco, CA.

Company score

Sentiment: -0.28; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.14; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.01; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.04; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.16; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive